ATE240139T1 - Co-kristallisationsprozess - Google Patents

Co-kristallisationsprozess

Info

Publication number
ATE240139T1
ATE240139T1 AT00910766T AT00910766T ATE240139T1 AT E240139 T1 ATE240139 T1 AT E240139T1 AT 00910766 T AT00910766 T AT 00910766T AT 00910766 T AT00910766 T AT 00910766T AT E240139 T1 ATE240139 T1 AT E240139T1
Authority
AT
Austria
Prior art keywords
crystals
crystallization
enantiomers
chiral
crystal
Prior art date
Application number
AT00910766T
Other languages
English (en)
Inventor
Karl Reuter
Original Assignee
Reuter Chemische Appbau Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reuter Chemische Appbau Kg filed Critical Reuter Chemische Appbau Kg
Application granted granted Critical
Publication of ATE240139T1 publication Critical patent/ATE240139T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
AT00910766T 1999-03-05 2000-03-03 Co-kristallisationsprozess ATE240139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200648A EP1034826A1 (de) 1999-03-05 1999-03-05 Co-Kristallisationsverfahren
PCT/EP2000/001858 WO2000053283A1 (en) 1999-03-05 2000-03-03 Co-crystallization process

Publications (1)

Publication Number Publication Date
ATE240139T1 true ATE240139T1 (de) 2003-05-15

Family

ID=8239950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910766T ATE240139T1 (de) 1999-03-05 2000-03-03 Co-kristallisationsprozess

Country Status (8)

Country Link
US (1) US6570036B1 (de)
EP (2) EP1034826A1 (de)
JP (1) JP4896294B2 (de)
AT (1) ATE240139T1 (de)
AU (1) AU3285800A (de)
DE (1) DE60002679T2 (de)
ES (1) ES2199144T3 (de)
WO (1) WO2000053283A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1161290T3 (da) * 1999-03-17 2008-01-21 Reuter Chemische Appbau Kg Emulsionskrystallisering med genbrug
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN100360117C (zh) 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US20040110957A1 (en) * 2002-12-05 2004-06-10 Honeywell International, Inc. Process for the synthesis of an antiviral compound
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20090246288A1 (en) * 2004-02-25 2009-10-01 Pharmaceutical Industry Technology And Development Center Taste-masking oral dosage form and method of preparing the same
TWI335227B (en) 2004-02-25 2011-01-01 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
US8601530B2 (en) * 2006-09-19 2013-12-03 The Invention Science Fund I, Llc Evaluation systems and methods for coordinating software agents
CA2732157C (en) 2008-07-29 2016-04-12 Poxel Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
SI2413911T1 (sl) 2009-03-31 2014-04-30 Krka, D.D., Novo Mesto Progresivna emulzijska kristalizacija
US8716520B2 (en) 2010-01-15 2014-05-06 Lupin Limited Method of resolution of (RS)- 1,1′-BI-2-naphthol for obtaining enantiomeric pure I.E. (S)-(−)-1,1′-BI-2-naphthol and/or (R)-(+)-1,1′-BI-2-naphthol via co-crystal formation with optically active derivatives of γ-amino acids
EP2364977A1 (de) 2010-01-26 2011-09-14 Reuter Chemische Apparatebau KG Verfahren zur Enantiomerenanreicherung von 3-Methyl-1-(2-Piperidinphenyl)-1-Butylamin
AU2011227300A1 (en) 2010-03-16 2012-11-15 Imperial Sugar Company Process for the manufacture of cocrystallized sucrose - polyol natural sweeteners and products thereof
CN102633692B (zh) * 2012-04-11 2014-04-09 上海康福赛尔医药科技有限公司 一种光学活性左旋和右旋3-溴樟脑-8-磺酸的制备方法
CN102633690B (zh) * 2012-04-11 2014-04-09 上海康福赛尔医药科技有限公司 诱导结晶拆分外消旋樟脑磺酸制左旋和右旋樟脑磺酸方法
EP2671858A1 (de) 2012-06-08 2013-12-11 Université Catholique De Louvain Verfahren zur Racematspaltung von Etiracetam
WO2013186390A1 (en) 2012-06-15 2013-12-19 Farma Grs, D.O.O. Selective crystallization processes using reverse micelle and w/o microemulsion systems - multitask emulsion crystallization (mec)
JOP20190251A1 (ar) 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
BR112021010796A2 (pt) 2018-12-04 2021-08-24 Metys Pharmaceuticals AG Composições sinérgicas compreendendo r-2-(sulfonil substituído)-hexahidro-pirrolo[1,2-a]pirazin-6(2h)-onas e s-2- (sulfonil substituído)-hexahidro-pirrolo[1,2-a]pirazin-6(2h)-onas em uma relação não racêmica
HUE062575T2 (hu) 2018-12-04 2023-11-28 Metys Pharmaceuticals AG (R)-2-(2-oxopirrolidin-1-il)-butánamidot és (S)-2-(2-oxopirrolidin-1-il)-butánamidot nem-racém arányban tartalmazó szinergetikus kompozíciók
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
EP3986131A1 (de) 2019-06-24 2022-04-27 Philip Morris Products, S.A. Zusammensetzungen und verfahren zur parasitenbekämpfung
CN114728934B (zh) 2019-10-02 2024-08-27 托雷莫治疗股份公司 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
CN115698002A (zh) 2020-06-24 2023-02-03 菲利普莫里斯生产公司 用于寄生虫控制的组合物和方法
IL299338A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment, amelioration or prevention of fibrotic disease
EP3939578A1 (de) 2020-07-13 2022-01-19 Novaremed Ltd. Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
EP3964497A1 (de) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
EP4320109A1 (de) 2021-04-07 2024-02-14 Tolremo Therapeutics AG Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung bei der behandlung oder linderung von krebs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865311A (en) * 1958-09-28 1961-04-12 Ajinomoto Kk Process for continuous resolution of racemic amino acids
JPS5655360A (en) * 1979-10-15 1981-05-15 Hiroyuki Nohira Optical resolution of (+-)-phenylglycine and/or (+-)-camphor-sulfonic acid
JPS5686138A (en) * 1979-12-18 1981-07-13 Hiroyuki Nohira Optical resolution of (+-)phenylglycine and (+-)camphorsulfonic acid
GB9126832D0 (en) * 1991-12-18 1992-02-19 Sandoz Ltd Separation process
WO1996006080A1 (en) 1994-08-19 1996-02-29 Chiroscience Limited Process for the separation of the enantiomers of a bicyclic lactam
ES2182025T3 (es) 1996-03-10 2003-03-01 Reuter Chemischer Appbau Kg Procedimiento de separacion.
NL1004346C2 (nl) * 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.

Also Published As

Publication number Publication date
JP2002538228A (ja) 2002-11-12
DE60002679T2 (de) 2004-04-08
US6570036B1 (en) 2003-05-27
ES2199144T3 (es) 2004-02-16
EP1156864A1 (de) 2001-11-28
EP1156864B1 (de) 2003-05-14
DE60002679D1 (de) 2003-06-18
WO2000053283A1 (en) 2000-09-14
JP4896294B2 (ja) 2012-03-14
EP1034826A1 (de) 2000-09-13
AU3285800A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
ATE240139T1 (de) Co-kristallisationsprozess
ATE368660T1 (de) Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside
ATE418549T1 (de) Verfahren zur optischen reinigung von enantiomer angereicherten benzimidazolderivaten.
NO974779D0 (no) Fremgangsmåte for separasjon av en blanding av enantiomere
DE69333675D1 (de) Enzymatische Verfahren zur Aüftrennüng von Enantiomeren-Mischungen nützlich als Zwischenprodukte zur Herstellung von Taxanen
PT1025067E (pt) Processo para a cristalizacao de compostos impedidos estereoquimicamente
ES8601100A1 (es) Un procedimiento para producir 3-(3, 4-dihidroxifenil) serina
IT8922075A0 (it) Processo per l'inversione stereochimica di (2s,3s)-2-ammino-3-fenil-1 ,3-propandioli nei corrispondenti enantiomeri (2r,3r)
ATE268166T1 (de) Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol
DE50209620D1 (de) Verfahren zur Herstellung von kristallinem Cholinascorbat
ATE387425T1 (de) Verfahren zur herstellung von bicalutamid
DK0749969T3 (da) Fremgangsmåde til fremstilling af polymorf form I af d4T
PT880525E (pt) Processo para a preparacao de galantamina
NO20005259L (no) Fremgangsmåte for fremstilling av enantiomerrent N-metyl-N- [(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)etyl]-2,2- difenylacetamid
NO990159D0 (no) FremgangsmÕte for fremstilling av enantiomerisk anrikede N-acylazetidin-2-karboksylsyrer
PT89029A (pt) Processo para a preparacao de novos derivados substituidos de 20,21-dinoreburnamenina
DE602004006021D1 (de) Verfahren zur racematspaltung von nefopam
EE200400016A (et) Protsess 1,5-diarüül-3-trifluorometüül-delta²-pürasoliinide ratseemiliste ja enantiomeerselt puhaste derivaatide valmistamiseks
PT98726A (pt) Processo de transformacao do acido 2-(3-benzoilfenil)propionico-r(-) no isomeros(+)
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
FI875602A (fi) Optiskt aktivt tetrahydro-2-furanonderivat saosom miksobicid.
DK0924206T3 (da) Fremgangsmåde til fremstilling af (R)-3-hydroxy-4-butyrolacton anvendeligt til fremstilling af (R)-carnitin
DE69819479D1 (de) Verfahren zur herstellung eines enantiomers von narwedin
DE50204211D1 (de) Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on- und 1,3-Oxathiolan-5-on-Derivaten
GEP19991791B (en) Pharmacologically Active Enantiomers and Process for its Production

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156864

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution